| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Adding Androgen To ERT Improves Quality Of Life In Postmenopausal Women TORONTO, ON -- Sept. 23, 1998 -- A study of 16 postmenopausal women shows the addition of androgen, or methyltestosterone, to estrogen replacement therapy can improve women's overall feeling of emotional well-being, according to Dr. Peter Collins, from the Imperial College School of Medicine at the National Heart & Lung Institute and Royal Brompton Hospital, in London. Dr. Collins presented these findings at the ninth annual meeting of the North American Menopause Society (NAMS) in Toronto. The 18-month study included 16 patients of the Royal Brompton Hospital, suffering from Syndrome X. In the study, Dr. Collins and fellows set out to study patients who suffered from anginal symptoms despite having normal coronary arteries -- a condition known as Cardiological Syndrome X. This condition primarily affects postmenopausal women. These women were given Estratest(R) (1.25mg esterified estrogens, USP and 2.5 mg methyltestosterone) Tablets. While the study found no difference by adding methyltestosterone to estrogen therapy in the results of standard cardiovascular testing conducted on a treadmill, the corresponding quality of life survey of these patients showed a significant improvement in their emotional well-being. Further, the study showed no adverse cardiovascular effects in patients with the addition of testosterone. This concurs with previous studies by Dr. Collins, which showed an increase in coronary blood flow with testosterone. "Patients with Syndrome X often suffer from tiredness and fatigue and their symptoms can be difficult to treat," Dr. Collins said. "Our findings showed that adding testosterone to their estrogen therapy positively affected the emotional well-being of postmenopausal women with Cardiac Syndrome X."
|